Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer

Tae Hyun Kang; Sang Taek Jung

doi:10.3390/biom10030382

Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer

Tae Hyun Kang, Sang Taek Jung

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or tissue targeting. Therefore, antibody engineering for cancer therapeutics focuses on both functional efficacy of the constant region and tissue-or cell-specificity of the Fv region. In the functional aspect of therapeutic purposes, antibody engineers in both academia and industry have capitalized on the constant region of different IgG subclasses and engineered the constant region to enhance therapeutic efficacy against cancer, leading to a number of successes for cancer patients in clinical settings. In this article, we review IgG subclasses for cancer therapeutics, including (i) IgG1, (ii) IgG2, 3, and 4, (iii) recent findings on Fc receptor functions, and (iv) future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients.

Original language	English
Article number	382
Journal	Biomolecules
Volume	10
Issue number	3
DOIs	https://doi.org/10.3390/biom10030382
Publication status	Published - 2020 Mar

Bibliographical note

Funding Information:
Funding: This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund.

Funding Information:
This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Cancer therapy
Fc receptors
Immunoglobulin G
Therapeutic antibodies

ASJC Scopus subject areas

Biochemistry
Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/biom10030382

Cite this

@article{083ee4bfe0024396bc261a5e17b08266,

title = "Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer",

abstract = "The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or tissue targeting. Therefore, antibody engineering for cancer therapeutics focuses on both functional efficacy of the constant region and tissue-or cell-specificity of the Fv region. In the functional aspect of therapeutic purposes, antibody engineers in both academia and industry have capitalized on the constant region of different IgG subclasses and engineered the constant region to enhance therapeutic efficacy against cancer, leading to a number of successes for cancer patients in clinical settings. In this article, we review IgG subclasses for cancer therapeutics, including (i) IgG1, (ii) IgG2, 3, and 4, (iii) recent findings on Fc receptor functions, and (iv) future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients.",

keywords = "Cancer therapy, Fc receptors, Immunoglobulin G, Therapeutic antibodies",

author = "Kang, {Tae Hyun} and Jung, {Sang Taek}",

note = "Funding Information: Funding: This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund. Funding Information: This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = mar,

doi = "10.3390/biom10030382",

language = "English",

volume = "10",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer

AU - Kang, Tae Hyun

AU - Jung, Sang Taek

N1 - Funding Information: Funding: This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund. Funding Information: This work was supported by grants from the Bio & Medical Technology Development Program (2017M3A9C8060541), the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000) through the National Research Foundation of Korea funded by the Ministry of Science and ICT, and LG Chem Open Innovation Fund. Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/3

Y1 - 2020/3

N2 - The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or tissue targeting. Therefore, antibody engineering for cancer therapeutics focuses on both functional efficacy of the constant region and tissue-or cell-specificity of the Fv region. In the functional aspect of therapeutic purposes, antibody engineers in both academia and industry have capitalized on the constant region of different IgG subclasses and engineered the constant region to enhance therapeutic efficacy against cancer, leading to a number of successes for cancer patients in clinical settings. In this article, we review IgG subclasses for cancer therapeutics, including (i) IgG1, (ii) IgG2, 3, and 4, (iii) recent findings on Fc receptor functions, and (iv) future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients.

AB - The constant region of immunoglobulin (Ig) G antibodies is responsible for their effector immune mechanism and prolongs serum half-life, while the fragment variable (Fv) region is responsible for cellular or tissue targeting. Therefore, antibody engineering for cancer therapeutics focuses on both functional efficacy of the constant region and tissue-or cell-specificity of the Fv region. In the functional aspect of therapeutic purposes, antibody engineers in both academia and industry have capitalized on the constant region of different IgG subclasses and engineered the constant region to enhance therapeutic efficacy against cancer, leading to a number of successes for cancer patients in clinical settings. In this article, we review IgG subclasses for cancer therapeutics, including (i) IgG1, (ii) IgG2, 3, and 4, (iii) recent findings on Fc receptor functions, and (iv) future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients.

KW - Cancer therapy

KW - Fc receptors

KW - Immunoglobulin G

KW - Therapeutic antibodies

UR - http://www.scopus.com/inward/record.url?scp=85081016018&partnerID=8YFLogxK

U2 - 10.3390/biom10030382

DO - 10.3390/biom10030382

M3 - Review article

C2 - 32121592

AN - SCOPUS:85081016018

SN - 2218-273X

VL - 10

JO - Biomolecules

JF - Biomolecules

IS - 3

M1 - 382

ER -

Reprogramming the constant region of immunoglobulin g subclasses for enhanced therapeutic potency against cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this